Literature DB >> 31251985

Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees.

Y Jin1, D H Solomon2, P D Franklin3, Y C Lee4, J Lii5, J N Katz6, S C Kim7.   

Abstract

OBJECTIVE: To examine patterns of prescription opioid use before total joint replacement (TJR) and factors associated with continuous use of opioids before TJR.
DESIGN: We conducted an observational cohort study among Medicare enrollees aged ≥65 years who underwent TJR between 2010 and 2014. Preoperative opioid use was defined as having any opioid prescription in the 12-month period before TJR. Patients who had an opioid prescription every month for a 12-month period were defined as continuous users. We examined patients' demographics, pain-related conditions, medication use, other comorbidities, healthcare utilization and their association with use of opioids before TJR.
RESULTS: A total of 473,781 patients underwent TJR:,155,516 THR and 318,265 TKR. Among the total cohort, 60.2% patients had any use of opioids and of those, 12.4% used opioids at least once a month continuously over the 12-month baseline period. Correlates of continuous opioid use included African American race (OR = 2.14, 95% confidence intervals (CI) = 2.01-2.28, compared to White patients), history of drug abuse (OR = 5.18, 95% CI = 3.95-6.79) and back pain (OR = 2.32, 95% CI = 2.24-2.39).
CONCLUSIONS: In this large cohort of patients undergoing TJR, over 60% ever used opioids and 12.4% of them continuously used opioids in the 12-month prior to surgery. Utilization of opioids became more frequent and high-dosed near the surgery. History of drug abuse, back pain, and African American race were strongly associated with continuous use of opioids preoperatively. Further research is needed to determine short-term and long-term risks of preoperative use of opioids in TJR patients and to optimize pre- and post-TJR pain management of patients with arthritis.
Copyright © 2019 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Opioids; Osteoarthritis; Total joint replacement

Year:  2019        PMID: 31251985      PMCID: PMC6751003          DOI: 10.1016/j.joca.2019.05.023

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  5 in total

1.  NarxCare Scores Greater Than 300 Are Associated with Adverse Outcomes After Primary THA.

Authors:  Ahmed K Emara; Daniel Grits; Alison K Klika; Robert M Molloy; Viktor E Krebs; Wael K Barsoum; Carlos Higuera-Rueda; Nicolas S Piuzzi
Journal:  Clin Orthop Relat Res       Date:  2021-09-01       Impact factor: 4.755

2.  Associations between pre-surgical daily opioid use and short-term outcomes following knee or hip arthroplasty: a prospective, exploratory cohort study.

Authors:  Justine M Naylor; Natalie Pavlovic; Melissa Farrugia; Shaniya Ogul; Danella Hackett; Anthony Wan; Sam Adie; Bernadette Brady; Leeanne Gray; Rachael Wright; Michelle Nazar; Wei Xuan
Journal:  BMC Musculoskelet Disord       Date:  2020-06-22       Impact factor: 2.362

3.  Association of Physical Therapy Interventions With Long-term Opioid Use After Total Knee Replacement.

Authors:  Kosaku Aoyagi; Tuhina Neogi; Christine Peloquin; Maureen Dubreuil; Lee Marinko; James Camarinos; David T Felson; Deepak Kumar
Journal:  JAMA Netw Open       Date:  2021-10-01

4.  Opioid use and patient outcomes in an Australian hip and knee arthroplasty cohort.

Authors:  Phil Huang; Jack Brownrigg; Justin Roe; David Carmody; Leo Pinczewski; Benjamin Gooden; Matthew Lyons; Lucy Salmon; Ka Martina; Joanna Crighton; Michael O'Sullivan
Journal:  ANZ J Surg       Date:  2022-08-08       Impact factor: 2.025

5.  Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis.

Authors:  Mayura Shinde; Carla Rodriguez-Watson; Tancy C Zhang; David S Carrell; Aaron B Mendelsohn; Young Hee Nam; Amanda Carruth; Kenneth R Petronis; Cheryl N McMahill-Walraven; Aziza Jamal-Allial; Vinit Nair; Pamala A Pawloski; Anne Hickman; Mark T Brown; Jennie Francis; Ken Hornbuckle; Jeffrey S Brown; Jingping Mo
Journal:  BMC Musculoskelet Disord       Date:  2022-09-23       Impact factor: 2.562

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.